These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2905893)

  • 1. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates. An experimental approach to the treatment of Parkinson's disease.
    Garcia de Yebenes J; Fahn S; Mena MA; Pardo B; Casarejos MJ
    ASAIO Trans; 1988; 34(4):951-7. PubMed ID: 2905893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
    de Yebenes JG; Fahn S; Jackson-Lewis V; Mena MA
    Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG; Fahn S; Lovelle S; Jackson-Lewis V; Jorge P; Mena MA; Reiriz J; Bustos JC; Magariños C; Martinez A
    Mov Disord; 1987; 2(3):143-58. PubMed ID: 2904648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG; Fahn S; Jackson-Lewis V; Jorge P; Mena MA; Reiriz J
    J Neural Transm Suppl; 1988; 27():141-60. PubMed ID: 3165432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
    de Yébenes JG; Fahn S; Goodman R; Jamrosik Z; Pezzoli G; Popalski S
    Adv Neurol; 1990; 53():231-8. PubMed ID: 1978516
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrastriatal infusion of lisuride--a potential treatment for Parkinson's disease? Behavioral and autoradiographic studies in 6-OHDA lesioned rats.
    May CH; Guilarte TR; Wagner HN; Vogel S
    Neurodegeneration; 1994 Dec; 3(4):305-13. PubMed ID: 7842301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.
    Archer T; Palomo T; McArthur R; Fredriksson A
    Neurotox Res; 2003; 5(1-2):95-110. PubMed ID: 12832225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
    Moreau C; Rolland AS; Pioli E; Li Q; Odou P; Barthelemy C; Lannoy D; Demailly A; Carta N; Deramecourt V; Auger F; Kuchcinski G; Laloux C; Defebvre L; Bordet R; Duce J; Devedjian JC; Bezard E; Fisichella M; Devos D
    Neurobiol Dis; 2020 Jun; 139():104846. PubMed ID: 32205254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External and implanted pumps for apomorphine infusion in parkinsonism.
    Pollak P; Benabid AL; Limousin P; Gervason CL; Jeanneau-Nicolle E
    Acta Neurochir Suppl (Wien); 1993; 58():48-52. PubMed ID: 8109301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
    Cohen G
    Adv Neurol; 1987; 45():119-25. PubMed ID: 3030068
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical models of Parkinson's disease.
    Bankiewicz KS; Sanchez-Pernaute R; Oiwa Y; Kohutnicka M; Cummins A; Eberling J
    Curr Protoc Toxicol; 2004 Feb; Chapter 1():Unit1.8. PubMed ID: 23045097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
    Quesada A; Micevych PE
    J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical models of Parkinson's disease.
    Bankiewicz KS; Sanchez-Pernaute R; Oiwa Y; Kohutnicka M; Cummins A; Eberling J
    Curr Protoc Neurosci; 2001 May; Chapter 9():Unit9.4. PubMed ID: 18428552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine stimulation via infusion in the lateral ventricle.
    Biagioni F; Busceti CL; Molinaro G; Battaglia G; Giorgi FS; Ruggieri S; Fornai F
    Ann N Y Acad Sci; 2006 Aug; 1074():337-43. PubMed ID: 17105930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
    J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.